Sight Sciences, Inc. (SGHT) stock
Close on Nov 18, 2026Market cap $593.30MP/E –Yield –
Earnings
Sight Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Sight Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 3, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $24.90M | +25.1% | -$0.12 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $23.40M | +19.4% | -$0.08 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | $19.70M | +12.6% | -$0.24 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 4, 2026after the close | $20.40M | +6.8% | -$0.08 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $19.90M | -1.5% | -$0.16 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $19.60M | -8.4% | -$0.23 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $17.50M | – | -$0.28 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025after the close | $19.10M | +1.6% | -$0.23 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $20.20M | +1.0% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $21.40M | -8.9% | -$0.25 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024after the close | $18.80M | -8.3% | -$0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $20.00M | +7.0% | -$0.27 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $23.50M | +36.6% | -$0.30 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $18.80M | +26.2% | -$0.35 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 13, 2023after the close | $20.50M | +39.5% | -$0.35 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | $18.70M | +42.7% | -$0.46 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | $17.20M | – | -$0.50 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $14.90M | – | -$0.49 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 24, 2022after the close | $14.70M | – | -$0.34 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | $13.10M | – | -$0.43 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Sight Sciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| growth | FY2026 | +4% – +7% | +7% – +15% | Lowered | Aug 5, 2026 |
| revenue | FY2026 | $92.00M – $93.00M | $82.00M – $88.00M | Raised | Nov 4, 2026 |
| revenue guidance | FY2026 | $88.00M – $92.00M | $83.00M – $89.00M | Raised | Aug 5, 2026 |
| adjusted operating expensesnon-GAAP | FY2026 | $92.00M – $94.00M | $93.00M – $96.00M | Lowered | Nov 4, 2026 |
| adjusted operating expensesnon-GAAP | FY2026 | $92.00M – $94.00M | $93.00M – $96.00M | Lowered | Aug 5, 2026 |
| adjusted operating expenses increasenon-GAAP | FY2026 | +6% – +9% | – | New | May 6, 2026 |
| increase compared to 2025non-GAAP | FY2026 | +5% – +7% | – | Lowered | Aug 5, 2026 |
| Interventional Dry Eye segment revenue | FY2026 | $6.00M – $8.00M | – | Lowered | May 6, 2026 |
| Interventional Glaucoma segment revenue | FY2026 | $77.00M – $81.00M | – | New | May 6, 2026 |
| Interventional Glaucoma segment revenue growth | FY2026 | +2% – +7% | – | New | May 6, 2026 |
Guidance vs results
The last range Sight Sciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $76.00M – $78.00M | $77.40MΣ4Q | Within range |
| Q4 FY2021 | Revenue | $14.50M – $14.80M | $14.70M | Within range |
Guidance history
Every forecast Sight Sciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | adjusted operating expenses | FY2026 | $92.00M – $94.00M | Lowered |
| Nov 4, 2026 | revenue | FY2026 | $92.00M – $93.00M | Raised |
| Aug 5, 2026 | increase compared to 2025 | FY2026 | +5% – +7% | Lowered |
| Aug 5, 2026 | adjusted operating expenses | FY2026 | $92.00M – $94.00M | Lowered |
| Aug 5, 2026 | revenue guidance | FY2026 | $88.00M – $92.00M | Raised |
| Aug 5, 2026 | growth | FY2026 | +4% – +7% | Lowered |
| Aug 5, 2026 | year-over-year growth | FY2026 | +14% – +19% | Raised |
| Aug 5, 2026 | Interventional Dry Eye revenue | FY2026 | $9.00M – $11.00M | Lowered |
| Aug 5, 2026 | Interventional Glaucoma revenue | FY2026 | $79.00M – $81.00M | Lowered |
| May 6, 2026 | adjusted operating expenses increase | FY2026 | +6% – +9% | New |
| May 6, 2026 | Interventional Glaucoma segment revenue growth | FY2026 | +2% – +7% | New |
| May 6, 2026 | adjusted operating expenses | FY2026 | $93.00M – $96.00M | New |
| May 6, 2026 | Interventional Dry Eye segment revenue | FY2026 | $6.00M – $8.00M | Lowered |
| May 6, 2026 | Interventional Glaucoma segment revenue | FY2026 | $77.00M – $81.00M | New |
| May 6, 2026 | revenue | FY2026 | $83.00M – $89.00M | New |
| May 6, 2026 | revenue growth | FY2026 | +7% – +15% | New |
| Mar 4, 2026 | adjusted operating expenses | FY2026 | $93.00M – $96.00M | New |
| Mar 4, 2026 | revenue | FY2026 | $82.00M – $88.00M | New |
| Nov 6, 2025 | adjusted operating expenses | FY2025 | $90.00M – $92.00M | New |
| Nov 6, 2025 | revenue | FY2025 | $76.00M – $78.00M | New |
| Aug 7, 2025 | Surgical Glaucoma segment’s unmitigated tariff exposure would increase the segment’s cost of goods sold | FY2025 | $1.00M – $1.50M | New |
| Aug 7, 2025 | adjusted operating expenses | FY2025 | $101.00M – $105.00M | Reaffirmed |
| Aug 7, 2025 | revenue | FY2025 | $72.00M – $76.00M | Raised |
| May 8, 2025 | adjusted operating expenses | FY2025 | $101.00M – $105.00M | Lowered |
| May 8, 2025 | revenue | FY2025 | $70.00M – $75.00M | New |
| Mar 5, 2025 | adjusted operating expenses | FY2025 | $105.00M – $107.00M | New |
| Mar 5, 2025 | revenue | FY2025 | $70.00M – $75.00M | New |
| Nov 7, 2024 | adjusted operating expenses | FY2024 | $104.00M – $106.00M | New |
| Nov 7, 2024 | revenue | FY2024 | $81.00M – $83.00M | Reaffirmed |
| Aug 1, 2024 | adjusted operating expenses | FY2024 | $107.00M – $109.00M | Lowered |
| Aug 1, 2024 | revenue guidance expectations | FY2024 | $81.00M – $83.00M | Lowered |
| Mar 7, 2024 | adjusted operating expenses | FY2024 | $107.00M – $110.00M | New |
| Mar 7, 2024 | revenue | FY2024 | $81.00M – $85.00M | New |
| Aug 3, 2023 | average adjusted operating expenses on a quarterly basis | FY2023 | $30.50M | Reaffirmed |
| Aug 3, 2023 | revenue guidance expectations | FY2023 | $89.00M – $94.00M | Reaffirmed |
| May 4, 2023 | average adjusted operating expense | FY2023 | $30.50M | New |
| May 4, 2023 | revenue guidance expectations | FY2023 | $89.00M – $94.00M | Reaffirmed |
| Mar 13, 2023 | revenue | FY2023 | $89.00M – $94.00M | New |
| Nov 10, 2022 | revenue | FY2022 | $70.00M – $72.00M | Raised |
| Aug 11, 2022 | revenue | FY2022 | $68.00M – $72.00M | Narrowed |
| May 10, 2022 | revenue | FY2022 | $67.00M – $75.00M | Reaffirmed |
| Mar 24, 2022 | revenue | FY2022 | $67.00M – $75.00M | New |
| Jan 10, 2022 | total revenue | FY2021 | $48.80M – $49.10M | Raised |
| Jan 10, 2022 | total revenue | Q4 FY2021 | $14.50M – $14.80M | New |
| Nov 10, 2021 | revenue | FY2021 | $47.50M – $48.50M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Sight Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
See a number that looks wrong?